Purpose: Breast cancer is the most common cancer among women with ~1.67 million cases diagnosed annually worldwide, and ~1 in 37 women succumbed to breast cancer. Over the past decades, new therapeutic strategy has substantially improved the curative effect for women with breast cancer. However, the currently available ER-targeted and HER-2-based therapies are not effective for triple-negative breast cancer patients, which account for ~15% of total breast cancer cases.
Introduction
Breast cancer is an severe public health problem and one of the leading causes of cancer-related death in women. 1 There has been a 20% increase in the number of reported breast cancer patients worldwide, which resulted in 522,000 deaths since 2008 according to recent epidemiologic studies. 2, 3 Initiation and progression of breast cancer occurrence have been attributed to both genetic and environmental factors.
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Zheng et al reported to be ER, PR, and HER-2 positive. 8 Dysregulation of ER expression has been observed in 60%-70% of breast cancer patients. 9, 10 Tamoxifen (TAM) is a nonsteroidal triphenylethylene derivative and known to compete with estrogen to inhibit ER activity associated with tumor cell growth. In clinics, TAM has been widely administrated to patients with early localized breast cancer, which could be removed by surgical resection and those with metastatic breast cancer as a mainstay hormone therapy to prevent the relapse of ERpositive cancers. 11, 12 However, ER-negative breast cancer is usually associated with worse short-term outcomes than ER-positive cancer and accounts for 20%-30% of all patients with breast cancers, which is especially common in women with breast cancer diagnosed at young age and those in African ancestry. 13 In consideration of limitations in current therapeutic modalities for ER-negative tumors, it has been pressingly needed to search for new prognostic tools and therapy targets.
Targeted therapy, also known as molecularly targeted therapy, refers to the modalities of cancer treatments featured by the suppression of malignant cell activity and cancer progression by targeting specific bioactive macromolecules especially functional proteins, but not simply killing all actively dividing cell as traditional chemotherapy. 14, 15 A number of target therapy modalities such as monoclonal antibodies, tyrosine kinase inhibitors, cyclin-dependent kinase inhibitors, mammalian target of rapamycin inhibitors, and poly ADP-ribose polymerase inhibitors have been successfully applied or showed great potential as novel effective treatments for patients with breast cancer. 16, 17 The roles of growth factors and mitogens in regulating the gene expression and cell apoptosis and differentiation were proved to be mediated by the Ras/MEK/ERK signaling cascade. 18 This pathway has been reported to be frequently activated in various human cancer types such as breast and prostate cancers. Thus, these major components of the Ras/MEK/ ERK pathway are ideal and important candidate targets for therapeutic intervention of breast cancer development. As expected, specific inhibitors targeting Ras, Raf, MEK, and other downstream proteins of the Ras/MEK/ERK pathway have been developed for antibreast cancer drugs, and some of them are currently being testing by clinical trials. 19 1,25-Dihydroxy vitamin D 3 (1,25-(OH) 2 D 3 ), a biologically active form of vitamin D 3 , is one of the major controlling hormones of intestinal calcium absorption. 20 In recent investigations, multiple new biological effects of 1,25-(OH) 2 D 3 has also been disclosed, including the inhibition of cell proliferation and induction of cell apoptosis, which are closely associated with cancer initiation and development. 21, 22 However, little is known about the potential roles of 1,25-(OH) 2 
cell invasion assay
Cell invasion assay was performed using a polyethylene terephthalate membrane (8 µm pore size) with Millicell hanging cell culture inserts and BD Matrigel (Millipore). The MCF-7 and MDA-MB-453 cells loaded into the upper chamber were treated with 0.1 µm TAM or with 1,25-(OH) 2 D 3 in the absence or presence of the ERK agonist (U46619). Conditioned medium containing 10% (v/v) FBS was added to each well, and breast cancer cells were allowed to invade by penetrating through the membrane during 24-hour incubation at 37°C. Cells that had migrated through the filter pores were fixed with methanol, stained with crystal violet, and the invasive potential of breast cancer cells was evaluated microscopically by counting the number of invading cells. More than three biological replicates were done for cell invasion evaluation.
cell cycle analysis
Cell cycle progression of breast cancer cells after designated treatments was analyzed by quantification of DNA content. Briefly, cultured breast cancer cells were harvested and fixed in 70% ethanol for 24-48 hours at 4°C, treated with ribonuclease to remove RNA contamination, and DNA was stained with propidium iodide (PI). Fluorescence of PI-stained cells was measured by flow cytometry. At least three biological repeats were performed for cell cycle progression analysis.
apoptosis analysis
Cultured breast cancer cells were harvested and stained with Annexin V FITC and PI (#V13242; Thermo Fishier Scientific) according to the manufacturer's protocol. Percentages of apoptotic cells in each group were detected by flow cytometry for calculation of the breast cancer cell apoptosis rates for three biological repeats.
Western blotting
Breast cancer cells were collected after specified treatments and lysed in RIPA buffer supplemented with protease inhibitor cocktail (Roche) for 30 minutes on ice. The protein concentration was determined via the BCA protein assay. Approximately 30 µg proteins of each group were boiled at 100°C for 5 minutes, separated by SDS-PAGE electrophoresis, and transferred into the PVDF membrane. These membranes were then blocked with 5% skim milk, incubated with first antibody at 4°C overnight, washed with tris-HCl buffer solution and tween-80 (TBST), incubated with the secondary antibody at room temperature for 1 hour, followed by washing by TBST. ECL luminescent reagent was added and the resultant signals were recorded on X-ray film in darkroom. The glyceraldehyde-3-phosphate dehydrogenase antibody was used as loading control.
Plasmid construction
For the overexpression of Ras gene in breast cancer cells, full-length Homo sapiens Ras genomic sequences based in NCBI were cloned and ligated onto pcDNA3.0 (Addgene, Watertown, MA, USA). The recombinant constructs were sequence verified through DNA sequencing by the Thermo Fishier Scientific.
statistical analysis
Statistical analysis in this study was performed using the GraphPad Prism software. Data were expressed as mean ± SD and subjected to Student's t-test for evaluation of the significance of differences between two groups. Each assay was biologically repeated for at least three times. Significant differences were defined by a P-value of ,0.05, ,0.01, or ,0.001.
Results
1,25-(Oh) 2 D 3 inhibited breast cancer cell proliferation, migration, and invasion
To investigate the influence of 1,25-(OH) 2 D 3 on breast cancer cell growth and motility, we first used ER-positive breast cancer MCF-7 cells and ER-negative breast cancer DA-MB-453 cells to perform cell growth assay. Cells were treated with different concentrations of 1,25-(OH) 2 D 3 for 48 hours, and the 0.1 µm TAM group was used as positive control. We showed that 1,25-(OH) 2 Figure 5D and E) . Also, the phosphorylation of MEK and ERK in breast cancer cells treated with 1,25-(OH) 2 D 3 was significantly upregulated by Ras gene overexpression (Figure 7) . Thus, our data strongly indicated that the activity of Ras/MEK/ ERK signal pathway was a major mechanism underlying 1,25-(OH) 2 D 3 -induced anticancer effect in both ER-positive and the ER-negative breast cancer cells.
Discussion
Breast cancer remains a leading cause of cancer morbidity and mortality among women all over the world. 23 Previous statistics showed that each year ~2,400 deaths of women with breast cancer occurred at ages below 45 years, and the majority of breast cancer-related deaths happened in women older than 45 years. 24 The survival rate for women with nonmetastatic breast cancer was reported to be 98.5%, but there is a significant drop of survival rate for patients with metastatic breast cancer, which ranges from 84% to 24%. 25 TAM is known to compete with estrogen to inhibit the ER activity associated with tumor cell activity and has been approved for treatment of postmenopausal women suffering from advanced breast cancer by the US Food and Drug Administration in 1977 and later for postsurgery adjuvant treatment to eradicate micrometastasis derived from primary breast cancer. 26 The antiestrogenic activity of TAM mediated 
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Zheng et al by ER has been well established and was the main reason for TAM treatment in ER-positive breast cancer; however, recent clinical studies applying TAM in treating patients with ER-negative breast cancers failed to produce significant benefits in terms of mortality reduction or inhibition of breast cancer recurrence. 27, 28 Thus, it is pressingly needed to develop novel effective therapeutic strategies for female patients with ER-negative and triple-negative breast cancers, the latter being an aggressive disease with worse clinical outcomes.
In this study, we found that TAM exhibited significant anticancer effects on both ER-positive and ER-negative breast cancer cells by inhibiting cell viability, proliferation, migration, invasion, and cell cycle progression, while promoting breast cancer apoptosis. However, the therapeutic efficacy of TAM on ER-negative breast cancer cells was found weaker than in the ER-positive ones, indicating that TAM alone was not an ideal chemotherapeutic strategy for treating ER-negative breast cancer. Thus, we investigated the functions of 1,25-(OH) 2 
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Zheng et al manner, companied by induced G0/G1 arrest and apoptosis. These cellular assays showed that 1,25-(OH) 2 D 3 possesses significant inhibitory effects on breast cancer cell activity.
The Ras/MEK/ERK mitogen-activated protein kinase cascade has been established as a key intracellular signaling pathway responsible for regulating diverse cellular functions including cell proliferation, survival, apoptosis, motility, transcription, metabolism, and differentiation, which are all closely associated with tumorigenesis. 29 Multiple components of this pathway were reported to be mutated or submit your manuscript | www.dovepress.com
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Zheng et al aberrantly expressed in human breast cancer cells and linked with poor prognosis of breast cancer patients. Moreover, the Ras/MEK/ERK pathway has also been associated with chemotherapeutic drug resistance in breast cancer. 30 Thus, it is reasonable to speculate that the Ras/MEK/ERK signaling pathway would be applied as an ideal target for therapeutic intervention of breast cancer progression. 19 In the present study, we found that 1,25-(OH) 2 D 3 depressed Ras expression level and the phosphorylation of MEK and ERK1/2 in both ER-positive and ER-negative breast cancer cells, suggesting the role of Ras/MEK/ERK signaling during breast cancer inhibition by 1,25-(OH) 2 D 3 . More importantly, we proved that the expression of Ki67 gene and the phosphorylation of MEK and ERK in both breast cancer cell lines treated with 1,25-(OH) 2 D 3 were significantly recovered by overexpression of Ras gene. Consistent with these molecular alterations, the alterations of breast cancer cell functions including growth, proliferation, migration, invasion, cell cycle progression, and apoptosis caused by 1,25-(OH) 2 D 3 were also remarkable suppression by Ras gene overexpression, which further validated that 1,25-(OH) 2 D 3 performs its inhibitory roles on breast cancer progression through modulation of the Ras/ MEK/ERK signaling pathway.
Conclusion
We have shown that 1,25-(OH) 2 D 3 possesses remarkable anticancer effects on both ER-positive and ER-negative breast cancer cells. Furthermore, our study identified the depressed activation of the Ras/MEK/ERK pathway by 1,25-(OH) 2 D 3 as one key underlying mechanism. Our findings provided a rationale for preclinical and clinical evaluation of 1,25-(OH) 2 D 3 alone or in combination with other chemotherapeutic drugs for breast cancer therapy, especially for the ER-negative breast cancer. 
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